ro 8-0576 has been researched along with oxidopamine in 7 studies
| Studies (ro 8-0576) | Trials (ro 8-0576) | Recent Studies (post-2010) (ro 8-0576) | Studies (oxidopamine) | Trials (oxidopamine) | Recent Studies (post-2010) (oxidopamine) |
|---|---|---|---|---|---|
| 214 | 63 | 67 | 8,630 | 6 | 2,407 |
| Protein | Taxonomy | ro 8-0576 (IC50) | oxidopamine (IC50) |
|---|---|---|---|
| Glyceraldehyde-3-phosphate dehydrogenase | Homo sapiens (human) | 8 | |
| DNA repair protein RAD52 homolog | Homo sapiens (human) | 0.779 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, Y; Liu, Z; Ren, T; Wu, N; Yang, X; Yuan, W | 1 |
| Chen, Y; Hong, X; Liu, Z; Song, L; Wu, N; Yang, X; Yuan, W | 1 |
| Che, JY; Gan, J; Liu, ZG; Song, L; Wang, WW; Xie, CL; Yuan, ML; Yuan, WE; Zhang, SF | 1 |
| Chen, C; Fan, Q; Huang, J; Pan, X; Wei, H | 1 |
| De Wolf, C; Downey, P; Michel, A; Scheller, D; Schwarting, R; Van Damme, X | 1 |
| Black, MA; Dearden, PK; Duncan, EJ; Gemmell, NJ; Parr-Brownlie, LC; Reynolds, JN; Smith, LM | 1 |
| Deng, M; Fang, Y; Gui, X; Huang, L; Lu, S; Zhang, S | 1 |
7 other study(ies) available for ro 8-0576 and oxidopamine
| Article | Year |
|---|---|
Sustained-release formulation of levodopa methyl ester/benserazide for prolonged suppressing dyskinesia expression in 6-OHDA-leisoned rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Delayed-Action Preparations; Disease Models, Animal; Dopamine Agents; Drug Combinations; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Reaction Time | 2011 |
Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Blotting, Western; Delayed-Action Preparations; Disease Models, Animal; Down-Regulation; Drug Carriers; Drug Combinations; Dyskinesia, Drug-Induced; Female; Lactic Acid; Levodopa; Microspheres; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Receptors, AMPA | 2012 |
Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats.
Topics: Adrenergic Agents; Animals; Benserazide; Blotting, Western; Corpus Striatum; Cyclic AMP-Dependent Protein Kinases; Dopamine Agents; Drug Combinations; Dyskinesias; Female; Fluorescent Antibody Technique; Lactic Acid; Levodopa; Microspheres; Neurons; Oxidopamine; Parkinson Disease; Phosphoproteins; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; tau Proteins; Transcription Factors | 2014 |
Neuroprotective effect of combined therapy with hyperbaric oxygen and madopar on 6-hydroxydopamine-induced Parkinson's disease in rats.
Topics: Animals; Apomorphine; Benserazide; Combined Modality Therapy; Drug Combinations; Glial Fibrillary Acidic Protein; Glutathione Peroxidase; Hyperbaric Oxygenation; Levodopa; Lipid Peroxidation; Male; Malondialdehyde; Nerve Degeneration; Neuroprotective Agents; Oxidative Stress; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-bcl-2; Rats, Wistar; Stereotyped Behavior; Substantia Nigra; Superoxide Dismutase; Tyrosine 3-Monooxygenase | 2015 |
Behavioural Assessment of the A2a/NR2B Combination in the Unilateral 6-OHDA-Lesioned Rat Model: A New Method to Examine the Therapeutic Potential of Non-Dopaminergic Drugs.
Topics: Adenosine A2 Receptor Antagonists; Animals; Benserazide; Benzothiazoles; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Combinations; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Receptors, N-Methyl-D-Aspartate | 2015 |
Striatal mRNA expression patterns underlying peak dose L-DOPA-induced dyskinesia in the 6-OHDA hemiparkinsonian rat.
Topics: Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Cytoskeleton; Drug Combinations; Dyskinesia, Drug-Induced; Functional Laterality; Gene Expression; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Random Allocation; Rats, Wistar; RNA, Messenger; Tyrosine 3-Monooxygenase | 2016 |
β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
Topics: Allylbenzene Derivatives; Animals; Anisoles; Antiparkinson Agents; Behavior, Animal; Benserazide; Catechol O-Methyltransferase; Corpus Striatum; Dopa Decarboxylase; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Drug Combinations; Drug Therapy, Combination; Female; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley | 2017 |